Registration and Networking
Welcome and Opening Remarks
Are trial sites ready for online patient recruitment?When it comes to online patient recruitment, the site-patient handover is critical and in this talk we will examine a case where Antidote was able to identify that sites in a certain study were underperforming compared to our usual benchmarks. Further investigation unveiled several problems at the site level that were causing patients to drop out of the recruiting process. After addressing these we saw an immediate improvement in the conversion funnel. We will also discuss how data-driven analysis can be used to optimise patient flow to the best performing sites.
Talk 2: The Digital Clinical Trial
Case Study: To be confirmed
Public Policy at Niti Aayog, Office of Vice Chairman, Niti Aayog, Government of India
Coffee and Networking Break
Talk 3: How can technology solve the problem of a lack of patients in clinical trials?
Case Study: Performing large scale patient-centric real-world evidence-based researchHealth research is going through a period of rapid change driven by increased understanding that the patient needs to be seen as more than just a source of data. Rapid digitisation is helping to increase patient engagement around their healthcare and at a higher level become partners in the drive towards improved medications, and equally important ongoing collaborators all the way from clinical trials into the real world. This session will look at:
▪ The growing importance of Real World Evidence and why this will start to become a continuum flowing from the clinical trial process
▪ The growing importance of digital approaches as a technology foundation for research with examples from recent case studies in areas such as Parkinsons.
▪ The increase in the usage of patients own devices combined with sensors to drive both an individual's understanding of their health and to capture data for use in research
Attendees will leave the session understanding:
▪ An understanding how research is starting to be built around the patient, and what this patient-
centricity means for all players.
▪ How an engaged patient will help increase the quality of clinical research
▪ Insights gained from recent pivotal large scale direct to patient research in Parkinsons patients.
Talk 4: Gathering data when human clinical trials are unethical or infeasibleClinical efficacy trials in people are not always feasible or ethical, thus hampering the development and testing of countermeasures for lethal or permanently disabling toxic agents (e.g. chemical, biological, radiological or nuclear substances). This talk will give a quick overview of how the FDA Animal Efficacy Rule overcomes this problem and examples of life-saving animal models for emerging infectious diseases such as Ebola. Case study will be presented on collaboration between academic, non-profit, public and private sector organisations to combat recent emergencies such as Ebola and Zika.
AI enabled BOTs for patient education & assistance
Capacity and capability of global clinical research- The challenge of the unmet need of collaborationMonitoring and delivery are key objectives to running efficient trials for industry and academic sponsors. Globally these remain a challenge due to siloed data, processes and lack of real time collaboration. The need to step back and look at these problems and interactions is going to be key to speed the drug discovery process and to be able to react to pandemic challenges.
How has the University of Southampton challenged the norm and developed a collaborative approach to clinical research across 80% of the NHS and Canada to shift the way sites and sponsors work together, underpinning clear and effective research management.
Lunch and Networking Break
Artificial Intelligence in Life Sciences : Giving Data LifeAging populations, longer life expectancy and increasing multi-chronic disease prevalence compound cost burdens on our societies. At the same time, new technologies drive exponential change and opportunity into an industry crucial to societies, yet slow to adapt and alarmingly vulnerable to attacks and disruption. Advancements in genomics, proteomics, etabolomics create new thresholds in innovation.
Meanwhile, the rising voice of the consumer is empowering individuals and in response, new players are entering and reshaping the industry.
For industry, processes, models and structures must be reinvented within and across entities and industry itself must eliminate inefficiencies and reduce waste in the system.
Therefore there is a persistent drive to understand and deliver value, focused on improving efficiencies, increasing automation and reducing variability. To do this industry members must deploy a robust data strategy and leverage enterprise data to drive services and engagement to deliver the best to populations managed.
Talk 6: Democratizing AI for better outcomesTo understand how technology can advance healthcare and life sciences.
Talk 7: Building an End-To- End Strategy for Patient EngagementAnd, how new technologies are enabling continuous patient engagement through the product itself,
particularly the collection of data on how patients use drugs and devices, how new technologies are enabling continuous patient engagement through the product itself, particularly the collection of data on how patients use drugs and devices.
Coffee and networking break
Talk 8: To be confirmedIn this session we will aim to identify strategies that companies are adopting to respond to challenges facing industry in its ambition to become more patient centric such as regularity uncertainty, data safety & privacy and low health literacy etc.
Talk 9: Tackling Patient Centricity & Diversity Challenges in Clinical TrialsThere’s a lot of talk about patient centricity in the clinical trial arena these days, and for good reason—hearing the voice of patient and incorporating patient perspectives into trial design can pay huge dividends for all stakeholders involved. But what does it mean to be patient centric, practically speaking? What tactics are leading pharma companies employing to make centricity a reality in their trials?
The speaker will describe their recent patient centricity initiatives, the technologies they’ve employed, and the specific benefits their efforts have yielded for their companies and their patients. In this session, they discuss programs related to patient diversity and patient recruitment at their firms and take an industry-wide look at noteworthy innovations in patient centricity.